My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pliant Therapeutics, Inc. - Common Stock (NQ:PLRX)

1.630 +0.060 (+3.82%)
Streaming Delayed Price Updated: 2:19 PM EDT, Oct 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pliant Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Pliant Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics Presentations at The Liver Meeting® 2023 Highlight Bexotegrast, an Inhibitor of αvß6 and αvß1 Integrins, in Primary Sclerosing Cholangitis
INTEGRIS-PSC interim results highlighted in an oral late-breaker presentation 
From Pliant Therapeutics, Inc.
Via GlobeNewswire
The Latest Analyst Ratings for Pliant Therapeutics
 
Via Benzinga
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Where Pliant Therapeutics Stands With Analysts
 
Via Benzinga
Expert Ratings for Pliant Therapeutics
 
Via Benzinga
Pliant Therapeutics to Participate in Upcoming Investor Conferences
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer Highlight PLN-101095, A Novel Inhibitor of Integrins αvβ8 and αvβ1
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics Announces Three Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Where Pliant Therapeutics Stands With Analysts
 
Via Benzinga
Pliant Therapeutics INTEGRIS-PSC Phase 2a Interim Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in an Oral Late-Breaking Presentation at The Liver Meeting® 2023
Interim results from INTEGRIS-PSC to be featured in an oral presentation on Monday, November 13 
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics Appoints S. Mishima Gerhart as Chief Regulatory Officer
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Johnson Controls International To Rally Over 27%? Here Are 10 Other Analyst Forecasts For Wednesday
Keybanc cut the price target for Danaher Corporation (NYSE: DHR) from $325 to $300. Keybanc analyst Paul Knight maintained an Overweight rating. Danaher shares rose 0.6% to $248.75 in pre-market... 
Via Benzinga
Pliant Therapeutics Reveals Encouraging Data From Liver Disease Trial
Pliant Therapeutics Inc (NASDAQ: PLRX) announced data from the INTEGRIS-PSC Phase 2a trial of bexotegrast in patients with primary sclerosing cholangitis (PSC) and suspected  
Via Benzinga
Why TD SYNNEX Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Soleno Therapeutics, Inc. (NASDAQ: SLNO) shares jumped 318.5% to $18.54 after the company released top-line results from randomized withdrawal period of study C602 of DCCR for Prader-Willi... 
Via Benzinga
Why Shares of Pliant Therapeutics Are Rising Tuesday
The company's lead therapy fared well in a phase 2a trial to treat two separate conditions. 
Via The Motley Fool
Fisker, Intercept Pharmaceuticals, Immunovant And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Dow Jones falling around 200 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Pre-market stock movers are among the biggest topics worth checking out on Tuesday and we have the latest news for investors! 
Via InvestorPlace
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis
From Pliant Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
Pliant Therapeutics to Host Investor Call and Webcast to Discuss Interim Results from INTEGRIS-PSC, a Phase 2a Trial in Patients with Primary Sclerosing Cholangitis
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics Appoints Minnie Kuo as Chief Development Officer
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Friday
  Friday's session saw 169 companies set new 52-week lows. 
Via Benzinga
Pliant Therapeutics Announces Presentations at the European Respiratory Society International Congress 2023
From Pliant Therapeutics, Inc.
Via GlobeNewswire
IPF Has A 0% Survival Rate Without Lung Transplant And A Median Survival Time Of 2-5 Years From Diagnosis – Could GRI-0621 Be The Solution?
Idiopathic Pulmonary Fibrosis (IPF) is a serious chronic lung disease characterized by the thickening and stiffening of the lung tissue surrounding the air sacs. The exact cause of IPF is unknown, but... 
Via Benzinga
Pliant Therapeutics to Participate in Upcoming Investor Conferences
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics Announces Three Upcoming Presentations at the European Respiratory Society International Congress 2023
From Pliant Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics Announces Initiation of BEACON-IPF, a Phase 2b Clinical Trial of Bexotegrast in Idiopathic Pulmonary Fibrosis
Follows positive data from INTEGRIS-IPF Phase 2a trial 
From Pliant Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.